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ABSTRACT
U94, the latency gene of human herpesvirus 6, was found to inhibit migration, 
invasion and proliferation of vascular endothelial cells (ECs). Because of its potent 
anti-migratory activity on ECs, we tested the capability of U94 to interfere with the 
individual steps of the metastatic cascade. We examined the U94 biological activity 
on the human breast cancer cell line MDA-MB 231, as a model of highly aggressive 
cancer cell. Here we show that the expression of U94 delivered by an HSV-1-based 
amplicon promoted down-modulation of Src and downstream molecules linked to cell 
motility and proliferation. Indeed, U94 expression strongly inhibited cell migration, 
invasiveness and clonogenicity. We investigated the effects of U94 in a three-
dimensional rotary cell-culture system and observed the ability of U94 to modify 
tumor cell morphology by inducing a partial mesenchymal-to-epithelial transition. In 
fact, despite U94 did not induce any expression of the epithelial marker E-cadherin, 
it down-modulated different mesenchymal markers as β-catenin, Vimentin, TWIST, 
Snail1, and MMP2. In vivo data on the tumorigenicity of MDA-MB 231 displayed the 
capability of U94 to control tumor growth, invasiveness and metastasis, as well as 
tumor-driven angiogenesis. The antitumor U94 activity was also confirmed on the 
human cervical cancer cell line HeLa. The ability of U94 to inhibit cell growth, invasion 
and metastasis opens the way to a promising field of research aimed to develop new 
therapeutic approaches for treating tumor and cancer metastasis.
INTRODUCTION
Latency is an evolutionary mechanism that some 
viruses have exploited in order to survive in a hostile 
microenvironment. Chief among virus families known 
to be capable of latency are the herpesviruses, a widely 
distributed family of large, enveloped DNA viruses 
that are important pathogens in the human host. During 
herpesvirus latency, only a handful of genes are expressed, 
being able to silence most viral genes linked to active 
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virus replication and, in turn, to modulate different 
host cell functions, particularly those affecting the life 
span and proliferative potential of the latently infected 
cells. The human beta-herpesvirus subfamily includes 
two viruses, herpesvirus type 6 (HHV-6) A and B. 
These two viruses share molecular mechanisms of viral 
latency, during which specific transcripts from the viral 
gene U94 are expressed [1]. Interestingly, U94 displays 
DNA binding [2], exonuclease and helicase-ATPase 
activities [3]. In addition, U94 inhibits gene transcription 
and cell transformation by Harvey (H)-ras and bovine 
papillomavirus type 1 (BPV-1) viruses [4] as well as 
transcription from the human immunodeficiency virus 
type 1 (HIV-1) and human papillomavirus type 16 (HPV-
16) [5]. Such activities suggest a role for U94 in viral gene 
regulation and DNA replication.
More recently, human endothelial cells (ECs) were 
found to be susceptible to HHV-6 infection [6, 7] forming a 
site where the virus can persist in the absence of cytopathic 
effect and establish a latent infection. U94 expression in 
ECs in the absence of other viral transcripts was found to 
be associated to inhibition of different angiogenetic steps. 
In particular, U94 expression strongly inhibited in vitro 
capillary-like structures formation, sealing of a mechanical 
injured EC monolayer, angiogenesis and vasculogenesis 
ex vivo [8], all activities linked to the control of migration, 
invasion and proliferation of vascular ECs.
In this report, we explore the in vitro U94 activity on 
two different human cancer cell lines and provide evidence 
that the viral protein down-modulates the proto-oncogene 
Src activation and downstream signaling pathways. At 
the same time, we found that U94 expression induces a 
partial mesenchymal-to-epithelial transition and impairs 
cell migration, invasion and proliferation. Data on the 
tumorigenicity in NOD/SCID mice showed that despite 
a rapid loss of the U94 transgene expression, the viral 
protein does exert a long-term control of tumor growth, 
invasiveness and metastasis.
RESULTS
U94 expression in amplicon-transduced cells
Amplicons were titrated on Vero 2-2 cells (Figure 
1A). To define the optimal condition to obtain a maximum 
number of U94-expressing (U94+) cells, MDA-MB 
231 cells were infected at different MOI and EGFP 
fluorescence was measured by flow cytometry. The highest 
efficiency of viral infection (range from 80 to 93%) was 
obtained at MOI 1 for all tested constructs (Figure 1B). 
The persistence of U94 expression in MDA-MB 231 
cells was verified by RT-PCR analysis (Figure 1C). U94 
transcripts were detected at day 2 post infection (p.i.), 
whereas a faint or no expression was evident at day 4 and 
8 p.i., respectively (Figure 1C).
U94 inhibits cell proliferation
No toxicity was observed in MDA-MB 231 cells 
infected for 48 h with the different amplicon vector 
stocks compared to not treated (NT) cells (Figure 2A). 
However, at day 6 and 9 p.i., a significant reduction in 
cell proliferation was observed in U94+ cells compared 
to control EGFP-expressing (EGFP+) or NT cells (Figure 
2B). We measured cell cycle distribution of U94+ cells 
and found a significant arrest in the S-phase at day 6 p.i., 
compared to EGFP+ and NT cells (Figure 2C). This arrest 
was transient since it was not detected at day 9 p.i. In 
contrast, an increased – even if not statistically significant 
– G2/M cell cycle entry of U94
+ cells, as compared 
to control, cells is indicative of active cell division at 
day 9 p.i. This finding attests for a reversible S-phase 
block operated by U94, possibly related to the transient 
expression of the viral protein in MDA-MB 231 cells.
U94 inhibits cancer cell motility, invasion and 
anchorage-independent growth
The capability of U94 to interfere with the migratory 
activity of cells was assessed by wound healing assay. NT 
or EGFP+ MDA-MB 231 cells reached 100% of sealing 24 
h after the wound. At the same time, U94+ cells reached 
10% of sealing only (range from 5% to 15%), showing 
a strong inhibition in wound repair ability (Figure 3A). 
Cell movement along the bottom of an angled flask was 
recorded after 8 days. Cell migration strongly decreased 
in U94+ cells as compared to NT or EGFP+ cells, attesting 
for a long-standing anti-migratory efficacy of U94 (Figure 
3B). MDA-MB 231 cells are highly aggressive and 
metastatic, and tumor cell invasion is one of the key steps 
in this complex process. As the metastatic potential of 
tumor cells is largely dependent on their ability to degrade 
and migrate through the extracellular matrix (ECM), we 
examined the ability of NT, U94+ and EGFP+ MDA-MB 
231 cells to invade ECM. Fourthy-eight h p.i., invasion 
of U94+ cells was strongly reduced as compared to NT or 
EGFP+ cells (Figure 3C, left panel). Quantitative analysis 
demonstrated that only 4.9% of U94+ cells were able to 
invade the matrigel and the filter compared to 58% of 
EGFP+ and 59% of NT cells (Figure 3C, right panel). 
This result suggests that U94+ MDA-MB 231 cells have a 
much lower invasive potential than control cells in vitro. 
The ability for cancer cells to migrate and survive in the 
circulation is required for metastasis dissemination [9]. 
Adaptation to new environment is a hallmark of aggressive 
tumors and to survive, cancer cells have to grow and 
expand in the absence of attachments by overcoming 
anoikis [10]. The expression of U94 significantly inhibited 
the colony-forming ability of MDA-MB-231 cells 
compared to EGFP+ or NT cells (Figure 3D, left panel) 
in an anchorage-independent environment (soft agar). In 
fact, an approximately 60% decrease in colony number 
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was observed in U94+ (91 ± 7) compared to EGFP+ or NT 
cells (222 ± 14 and 223 ± 21, respectively) (Figure 3D, 
right panel).
U94 expression in MDA-MB 231 cells leads to 
a partial mesenchymal-to-epithelial transition 
(MET)
In order to study cell-cell interaction upon U94 
expression, we used the Rotary Cell Culture System 
(RCCSTM, Synthecon, Inc.) to generate a 3D cell culture 
microenvironment. After two days in 3D fluid-dynamic 
culture, spheroids formed by NT, U94+ or EGFP+ MDA-
MB 231 cells were harvested as previously described 
[11] and morphologically examined by the classical 
hematoxylin and eosin (H&E) staining. As shown in Figure 
4A, more than 30% of NT and EGFP+ cells appeared 
isolated and characterized by nuclear and cytoplasmic 
alteration as pleomorphism, multinuclearity and “cell 
in cell” aspect. On the other hand, U94 expression was 
related to disappearance of atypias and increased cell-cell 
adhesion. Based on these data, we sought to understand if 
U94 was able to trigger a MET. In normal epithelial cells, 
β-catenin exhibits membranous staining, whereas excess 
of free β-catenin in the cytoplasm is rapidly degraded [12]. 
In transformed cells, excess of β-catenin accumulates in 
Figure 1: HSV-1 amplicons titration and characterization. (A) HSV-1 amplicon constructs were transduced into Vero 2-2 cells 
and EGFP expression was visualized by fluorescence microscopy. One day after infection, single cells expressing EGFP were representative 
of gene expression and cell transduction. In the right panel fluorescence images merged with corresponding bright field images to show 
Vero 2-2 cell morphology (original magnification 10x). (B) MDA-MB 231 cells were infected with amplicon vectors at different MOI and 
the EGFP expression was evaluated by flow cytometry. The percentage of positive cells is reported in the graph. (C) The presence of U94 
mRNA was analyzed by RT-PCR in MDA-MB 231 cells infected with amplicon constructs at different days p.i. K-, negative control, water; 
K+, positive control, plasmid expressing U94.
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the cytoplasm owing to impairment of its degradation 
[13], leading to its translocation into the nucleus, where it 
acts as transcriptional factor able to activate several genes 
involved in oncogenesis [14, 15]. Immunohistochemistry 
(IHC) of spheroids showed a cytoplasmic expression 
of β-catenin in control cultures, whereas it was mostly 
(≥ 90% of cells) confined at the cell membrane in U94+ 
cultures, (Figure 4B). Since relocation of β-catenin from 
cytoplasm to cell membrane is indicative of a switch of 
tumor cells from an aggressive to a more differentiated 
phenotype, our data corroborate the hypothesis on the 
role of U94 in triggering a MET. Vimentin is another 
marker of epithelial-to-mesenchimal transition (EMT), 
whose expression is transactivated by β-catenin [16]. 
Figure 2: U94 expression inhibits cell proliferation and transiently arrests cells in S-phase. (A) The number of viable cells 
in culture was determined by quantification of the ATP, which signals the presence of metabolically active cells. Data are shown as cell 
viability (%) by comparing the infected groups with the NT cells, the viability of which was assumed to be 100%. (B) At each time point, 
cells were counted using the trypan blue exclusion method. Bars represent the mean ± SD of three independent experiments performed 
in triplicate. (C) On the days indicated, U94+, EGFP+ and NT cells were stained with propidium iodide and the cell cycle profile was 
determined by flow cytometry. Upper panels, FACS analysis is representative of three independent experiments with similar results. Lower 
panels, data (mean ± SD) are representative of three independent experiments. Statistical analysis was performed by 1-way ANOVA, and 
the Bonferroni post-test was used to compare data (*P < 0.05).
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Vimentin is overexpressed in several aggressive breast 
cancer cell lines and correlated with increased tumor cell 
migration and invasion [17]. Loss of vimentin expression 
exhibits inhibition of motility and invasiveness of MDA-
MB 231 cells, which constitutively express vimentin 
[18]. As shown in Figure 4C, vimentin was found to be 
expressed as cytoplasmic dots in less than 2% of U94+ 
cells, whereas approximately 45% of control cells did 
express it as both diffuse staining and punctate dots in 
the cytoplasm. On the other hand, any attempt to detect 
E-cadherin, an epithelial marker and suppressor of tumor 
cell invasion and metastasis in U94+ MDA-MB 231 cells 
was unsuccessful (Figure 4D). As demonstrated by real-
time-PCR, U94 expression also induced a strong down-
modulation of TWIST, a well-established transcription 
factor inducing EMT and promoting tumor invasion and 
metastasis [19], as well as a concomitant down-regulation 
of the mesenchymal markers N-cadherin, Snail1, and 
MMP2 (Figure 4E). Taken together these results support 
a role for U94 in triggering a partial MET of MDA-MB 
231 cells.
U94 inhibits Src and downstream signaling 
cascade
Western blot analyses were performed to determine 
whether U94 effects on MDA-MB 231 cells were 
mediated by down-modulation of signaling pathways 
usually involving tumor cell motility, invasion and 
proliferation. As shown in Figure 5, immunoblotting 
of U94+ MDA-MB 231 cell lysates showed that pSrc 
(pY418) levels dramatically decreased as compared to 
control cells (Figure 5, left panels). Down-modulation of 
pSrc resulted in the concomitant inactivation of β-catenin 
(pY654), STAT3 (pY705), Cortactin (pY421), ARP2/3 
and Akt (pS473). Quantification of data from multiple 
experiments are shown in Figure 5 (right panels). At 
the same time, EGFP+ cells did not show any inhibition 
of the above signaling pathways when compared to NT 
cells. Specificity of inhibition of the proto-oncogene Src 
and its downstream substrates by U94 was confirmed by 
the evidence that other signaling pathways summoned 
to promote cancer cell invasion and metastasis, such as 
Figure 3: U94 expression inhibits MDA-MB 231 cell migration, invasion and clonogenicity. (A) Confluent cell monolayers 
were scratched using a 200 μl pipette tip and sealing of the wound was recorded by light microscopy over a 24 h time course after wound 
scratch (original magnification 10x). (B) Cell movement along the bottom of an angled flask was recorded at day 8 p.i. (C) Cell invasion 
assay was performed by Matrigel-coated transwell system. Cells were resuspended in a serum-free medium and seeded in the upper 
chamber. Complete medium was used as chemoattractant factor in the lower chamber. After 48 h of culture, migrated cells were stained, 
photographed and counted (original magnification 10x). (D) Colony forming ability of MDA-MB 231 cells infected or not with amplicons. 
Cells were plated into six-well plates and, after two days, the medium was replaced using fresh medium. Cell growth was analyzed by 
using MTT (original magnification 10x). Data represent the average of three independent experiments performed in triplicate. Images 
are representative of three independent experiments with similar results. Statistical analysis was performed by 1-way ANOVA, and the 
Bonferroni post-test was used to compare data (** P < 0.01; *** P < 0.001).
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Figure 4: U94 expression induces a partial MET in MDA-MB 231 cells. After 3D culture, cells were harvested and processed 
for staining. Five μm thick sections were prepared and stained with (A) H&E for morphological analysis, or IHC for (B) β-catenin, (C) 
Vimentin, and (D) E-cadherin expression. (Original magnification: 20x upper panels; 40x lower panels). The arrows in panel A show 
cytonuclear atypias, such as nuclear pleomorphism, multinuclearity (black arrow) and “cell in cell” aspects (red arrow). (E) Real-time-PCR 
analysis of mesenchymal markers Snail1, Twist, MMP-2 and N-Cadherin was performed on NT cells and on EGFP+ and U94+ cells at day 
4 p.i. Gene expression is represented as relative mRNA levels. Data represent the mean (± SD) of three independent experiments performed 
in triplicate.
Figure 5: Effect of U94 on cell signaling pathways. Western blot analysis of MDA-MB 231 lysates was performed using mAbs 
to Src pTyr418, total Src, β-catenin pTyr654, total β-catenin, FAK pTyr397, total FAK, STAT3 pTyr705, total STAT3, Cortactin pTyr421, 
total Cortactin, ARP2/3, GAPDH, Akt pSer473, total Akt, ERK pThr202 and total ERK as specific reagents. Quantification was carried 
out by densitometric analysis and plotting of the Src pTyr418/Src, β-catenin pTyr654/β-catenin, FAK pTyr397/FAK, STAT3 pTyr705/
STAT3, Cortactin pTyr421/Cortactin, ARP2/3/GAPDH, Akt pSer473/Akt and ERK pThr202/ERK. Left panels, blots are representative of 
three independent experiments with similar results. Right panels, values reported are the means ± the SD of three independent experiments. 
Statistical analysis was performed by 1-way ANOVA, and the Bonferroni post-test was used to compare data (* P < 0.05; ** P < 0.01; *** 
P < 0.001).
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FAK and ERK [20], were not affected by the viral protein 
(Figure 5).
U94 expression impairs tumor growth in NOD/
SCID mice
To further investigate the effect of U94 on tumor 
progression in vivo, NT, EGFP+ or U94+ MDA-MB 231 
cells were injected into the dorsolateral flank of NOD/
SCID mice. Tumor growth was monitored and tumors 
were excised and weighed 23 days after injection. U94 
expression caused a dramatic delay of tumor take when 
compared to NT or EGFP+ tumors. U94+ tumors resulted 
to be smaller compared to control tumors, suggesting that 
U94 supports inhibition of tumor growth (Figure 6A). The 
average weight of tumors derived from NT, EGFP+ and 
U94+ cells were 0.26 ± 0.02, 0.29 ± 0.01 and 0.10 ± 0.01 
g, respectively (Figure 6B). At day 23 after tumor cells 
injection, tumor growth was strongly inhibited in each 
mouse inoculated with U94+ cells compared to controls 
(Figure 6C). IHC analysis of biopsies revealed consistent 
morphological differences between tumors generated 
by U94+ cells and control tumors generated by NT or 
EGFP+ cells. H&E staining of U94+ xenografted tumors 
showed that nodules were small, closely knit and very 
well defined. On the contrary, control tumor biopsies were 
characterized by fat invasion, which is a poor prognosis 
factor for cancer development [21] (Figure 6D, upper 
panels) and distinguished by the presence of blood vessels 
which almost missed in U94+ tumors (Figure 6D, middle 
panels). Moreover, control biopsies presented severe 
cellular atypias attested by the presence of clearly visible 
Figure 6: U94 expression impairs tumor growth in vivo. Twenty-tree days after cell injection, mice were sacrificed; tumors were 
(A) measured and (B) weighted. (C) a representative picture of one tumor of each group is reported (n=8-10 mice/group). Data are mean ± 
SEM. In box and whiskers graphs, boxes extend from the 25th to the 75th percentiles, lines indicate the median values, and whiskers indicate 
the range of values. (*** P < 0.001). Tumors were processed for IHC. Five μm thick sections were prepared and stained with (D) H&E for 
morphological analysis. (Original magnification: 10x upper panels; 20x middle panels 40x lower panels).
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spindle-shaped cells as compared to U94+ biopsies (Figure 
6D, lower panels). Moreover, IHC analysis of biopsies 
showed that U94+ xenografted tumors displayed weak 
dot-like cytoplasmic expression of vimentin, whereas 
tumors generated by NT or EGFP+ cells showed abundant 
and largely diffused cytoplasmic expression of vimentin 
(Figure 7A). As expected, the expression of E-cadherin 
was not detected in NT and EGFP+ as well as in U94+ 
biopsies (Figure 7B). In vivo results confirm the ability 
of U94 to promote a partial MET. RT-PCR analysis of 
biopsies revealed that U94 transcripts were expressed in 
U94+ cells before their injection into mice but not in the 
excised tumors (Figure 7C). This result suggests that even 
if expression of U94 transcripts is limited at first stages 
of tumor engraftment, this is sufficient to strongly inhibit 
tumor growth and local invasion.
U94+ tumor cells are able to condition the 
microenvironment inducing lack of angiogenesis 
in xenografted tumors
A polyclonal antibody to mouse CD31 was used 
to identify blood vessels infiltrating xenografted tumors. 
IHC analysis showed that tumors derived from NT or 
EGFP+ cells were highly vascularized (Figure 8A). On the 
other hand, sections of tumors derived from U94+ cells 
showed a decreased number of tiny blood vessels with 
a small – and sometime lacking – lumen. The evidence 
of a strongly impaired vasculogenesis in tumor sections 
derived from U94+ cells is quite surprising, being that the 
neo-vasculature is of mouse origin and does not express 
U94. Previous ex vivo data showed that U94 treatment 
renders rat aortic rings insensitive to the potent VEGF-
induced vasculogenetic activity [8]. This finding suggests 
the capability of U94+ xenografts to promote a tumor 
microenvironment unfavorable to neo-vessel formation. 
To test this hypothesis, we investigated the effect of U94+ 
MDA-MB 231 cells conditioned culture medium on the 
angiogenetic activity of HUVECs. As shown in Figure 8B, 
HUVECs co-cultured for 24 h in the collagen-coated upper 
insert well of a 3 μm pore-size Transwell with U94+ cells 
in the lower chamber, completely lost their natural ability 
to form tube-like structures when detached and seeded on 
Matrigel. On the contrary, HUVECs co-cultured with NT 
or EGFP+ cells were capable of exerting angiogenesis, 
forming a consistent network of tube-like structures. 
Moreover, the presence of conditioned medium obtained 
from U94+ MDA-MB 231 on HUVECs monolayers 
impaired sealing of the wound, whereas this did not occur 
in HUVECs cultured with medium obtained from NT or 
EGFP+ MDA-MB 231 cells during the wound healing 
assay (Figure 8C). Even if mechanisms of inhibition 
remain to be elucidated, these data strongly support the 
hypothesis of a key role played by U94+ tumor cells in 
impairing vasculogenesis in vivo.
U94 decreases the ability of cancer cells to form 
metastasis in vivo
Additional in vivo experiments were performed 
to examine whether U94 is also able to modulate 
experimental lung metastasis formation. MDA-MB 
231 cells expressing or not U94 were injected into 
immunocompromised mice via the tail vein. Significantly 
reduced numbers of lung metastasis was observed in the 
U94+ group compared with the EGFP+ and NT control 
groups (Figure 9, left panel). Representative images are 
shown in Figure 9, right panels. Taken together our results 
suggest an inhibitory role of U94 in cancer progression, 
including experimental lung metastasis formation.
U94 is able to inhibit cell migration and 
proliferation of a different tumor cell line
The U94 inhibitory activity of migration and 
proliferation was also evaluated on HeLa – a human cell 
line derived from cervical cancer cells – by wound healing 
and soft-agar assays. The experiments were conducted at 
24 h p.i. with EGFP- and U94-expressing plasmids. At 
the end of the wound healing assay, control HeLa cells 
reached 100% of sealing, whereas cells transduced with 
U94 reached 25.8% healing only (range from 20.9% to 
30.6%) (Figure 10A). In the soft agar assay, expression 
of U94 significantly inhibited cell colony formation as 
compared to control cells. In particular, the colony number 
decreased from 189 ± 18 and 180 ± 3 for NT and EGFP+ 
cells respectively, to 90 ± 10 for U94+ cells (Figure 10B). 
Similarly to what we observed in MDA-MB 231, U94-
triggered effects on HeLa cells were associated with Src 
down-modulation (Figure 10C). To further investigate the 
effect of U94 on human cervical cancer progression in 
vivo, NT, EGFP+ or U94+ HeLa cells were injected into 
the dorsolateral flank of NOD/SCID mice. As for MDA-
MB 231 tumors, U94 expression caused a dramatic delay 
of tumor take when compared to NT or EGFP+ tumors. 
As shown in Figure 11A, tumor growth rate significantly 
decreased during the follow-up period, suggesting that 
U94 supports inhibition of HeLa tumor growth. The 
average weight of tumors derived from NT, EGFP+ and 
U94+ cells were 0.26 ± 0.01, 0.31 ± 0.03 and 0.18 ± 0.01 
g, respectively (Figure 11B). At day 23 after tumor cells 
injection, HeLa tumor growth was strongly inhibited in 
each mouse inoculated with cells expressing U94 as 
compared to controls (Figure 11C).
DISCUSSION
The ability of tumor cells to mobilize, invade 
and cross normally non-permissive tissue barriers is 
responsible for cancer dissemination. A necessary first 
step in metastasis consists in epithelial cancer cell 
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transition to a mesenchymal-like element via EMT. EMT 
comprehends coordinated molecular and cellular changes 
leading epithelial cancer cells to express mesenchymal 
markers, display a reduction in cell-cell adhesion and 
gain motility [22, 23]. After undergoing EMT, tumor 
cells can extravasate into secondary organs, where cancer 
cells establish a new niche for tumor cell attachment and 
growth [24, 25]. Inhibiting or reversing an EMT can be 
regarded as a safe strategy for limiting cancer invasion 
and progression.
The Src family members are classified as oncogenic 
proteins for their involvement in all aspects of tumor 
development and microenvironment remodeling 
[26]. Increased Src activity drives EMT by inducing: 
i) cytoplasmic accumulation of β-catenin leading to 
dissociation of cell-cell junctions [27]; ii) β-catenin 
transcriptional activity that in turn promotes EMT through 
Snail1 over-expression; iii) tyrosine phosphorylation 
of cortactin leading to cytoskeleton activation and cell 
motility [28]; and iv) activation of Twist, that promotes 
the generation of an aggressive cancer stem cell phenotype 
[29]. On the other hand, Src inhibition suppresses the EMT 
process in vitro and in vivo [30–32].
The results of the present study reveal the capability 
of the HHV-6 protein U94 to down-modulate Src activity 
and impact on cell proliferation and invasion. The 
strong impairment of motility upon U94 expression was 
concomitant to a reduced phosphorylation of β-catenin 
and to down-modulation of STAT3, Cortactin and Arp2/3. 
Moreover, U94+ cells cultured in 3D fluid-dynamic 
condition showed disappearance of characteristic tumor 
cell atypias that included a decreased appearance of 
Figure 7: U94 induces MET of xenografted tumor cells. Five μm thick sections were prepared and stained with antibodies 
against (A) vimentin and (B) E-cadherin (Original magnification: 20x upper panels; 40x lower panels). (C) the presence of U94 mRNA 
was analyzed by RT-PCR in MDA-MB 231 cells infected with HSV-1 amplicon constructs before injection in mice (Time 0) and in tumor 
biopsies 23 days after injection (a.i.). K-, negative control, water; K+, positive control, plasmid expressing U94.
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spindle shaped cells, indicating a switch from a highly 
aggressive phenotype to a less aggressive one. β-catenin 
re-localization at the cell surface of U94+ cancer cells 
together with a generally reduced cytoplasmic expression 
of vimentin was highly suggestive of MET. Indeed, 
molecular analysis confirmed down-modulation of the 
mesenchymal marker N-cadherin, accompanied by 
down-regulation of Twist and Snail1, both linked to EMT 
[33–35]. On the other hand, these cells did not show 
any re-expression of E-cadherin, a molecule essential 
for intercellular adhesion junctions and intimately 
connected to a cell degree of epitheliality in both 
morphology, migratory and invasive ability. E-cadherin 
expression is silenced by DNA hypermethylation [36] 
but it is also known that this epigenetic phenomenon 
can be reversed by microenvironmental factors [37]. 
Thus, our data indicate the incapability of U94 to trigger 
E-cadherin promoter demethylation and attest for the 
ability of viral protein to sustain a partial MET. One 
possible explanation for this phenomenon may reside 
in the lack of FAK and ERK down-modulation. In 
fact, both signaling pathways are known to be strongly 
Figure 8: U94 inhibits tumor-driven angiogenesis. (A) CD31 immunostaining of tumor biopsies (original magnification: 20x upper 
panels; 40x lower panels). (B) NT, EGFP+ and U94+ MDA-MB 231 cells were co-cultured with HUVECs. Twenty-four h after co-culture, 
HUVECs were seeded on BME-coated plates. Images were taken after 8 h of HUVEC culture on BME (original magnification 10x). (C) 
HUVEC confluent monolayers were scratched using a 200 μl pipette tip and cultured in the presence of medium obtained from NT, EGFP+ 
or U94+ MDA-MB 231 cells. Wound sealing was recorded by light microscopy over a 24 h time course after wound scratch (original 
magnification 10x). Data are representative of three independent experiments with similar results. Statistical analysis was performed by 
1-way ANOVA, and the Bonferroni post-test was used to compare data (** P < 0.01; *** P < 0.001).
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involved in EMT [38, 39]. Introduction of tumor cells 
into a secondary organ environment led to the passive 
loss of methylation of the E-cadherin promoter and re-
expression of this cell-cell adhesion molecule [37]. In 
fact, recent findings suggest that only non-EMT cells that 
have entered in the blood stream are able to reestablish 
colonies in the secondary sites, in light of cooperation of 
tumor cells with the microenvironment to become non-
invasive elements with acquired cell-cell adhesion and 
complete the process of metastasis [40]. Surprisingly, 
U94+ cells showed a strongly decreased capability of 
forming metastases in lung when they were directly 
inoculated into the bloodstream as compared to control 
cells. The initial arrest and adhesion of cancer cells to the 
vascular endothelium, as well as vascular permeability, 
are essential steps preceding cancer cell extravasation 
from the blood stream. In this respect, it is worth noting 
that Src plays a part in the endothelial permeability by 
promoting pathologic inflammatory processes [41, 42]. 
The decreased capability of U94+ cells to generate lung 
metastases may be at least in part due to Src inhibition. 
However, our finding is also suggestive of a role for U94 
in impairing tumor cell survival and/or growth during the 
metastatic process. In fact, U94 negatively impacts on 
Twist transcription, whose inhibition is known to reduce 
cancer cell proliferation and increase cell death [35]. In 
vivo experiments highlighted the potent and prolonged 
antitumor activity of U94. Despite the relatively short 
time expression of U94 transcripts in amplicon transduced 
cells (2-4 days), a long-term control of tumor growth and 
invasion is maintained, with significantly smaller tumor 
masses and in the absence of adipose tissue infiltration 
at the end of the study (23 days), compared to tumors 
generated by control cells. In particular, spindle cells 
with mesenchymal-like features were abundant in control 
tumors whereas they disappeared in the U94-conditioned 
ones. Moreover, angiogenesis was pronounced in control 
tumors but limited to few tiny vessels in those conditioned 
by U94. In this respect, it is worth noting that U94+ tumor 
cell conditioned medium was impairing the capability 
of ECs to migrate and promote angiogenesis in vitro. 
This finding adds more emphasis to our previous data 
showing that U94 is capable of rendering ECs insensitive 
to different pro-angiogenic stimuli, included VEGF [8]. 
Figure 9: U94 strongly inhibits lung metastatic foci formation. MDA-MB 231 cells were injected intravenously in mice (n=10 
mice/group). After 4 weeks, lungs were collected and macroscopic metastases were counted (left panel). A representative picture of one 
lung of each group is reported (right panels). Data are mean ± SEM. In box and whiskers graphs, boxes extend from the 25th to the 75th 
percentiles, lines indicate the median values, and whiskers indicate the range of values. (* P < 0.05).
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Figure 10: In vitro effect of U94 on HeLa cells. (A) wound healing assay, (B) cell clonogenic assay and (C) signaling pathway 
assay. Data represent the average of three independent experiments performed in triplicate. Images are representative of three independent 
experiments with similar results. Statistical analysis was performed by 1-way ANOVA, and the Bonferroni post-test was used to compare 
data (*** P < 0.001).
Figure 11: U94 expression on HeLa cells reduces xenografted tumor growth. Twenty-three days after HeLa cell injection, mice 
were sacrificed; tumors were (A) measured and (B) weighted. (C), a representative picture of one tumor of each group is reported. (n=8-10 
mice/group). Data are mean ± SEM. In box and whiskers graphs, boxes extend from the 25th to the 75th percentiles, lines indicate the median 
values, and whiskers indicate the range of values. (** P < 0.01; *** P < 0.001).
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The ability of U94 to condition the microenvironment and 
impact on EC angiogenetic activity both in vitro and in 
long-term in vivo experiments, is completely new and calls 
for further investigation aimed to identify and characterize 
mechanisms for such a relevant anticancer activity. U94-
mediated impairment of cancer progression through a 
“two compartments” activity may provide anticancer 
therapeutic benefits not only in terms of oncosuppressive 
effects on tumor cells but also by inhibiting the 
neovascularization process, thus hampering the tumor 
parenchymal/stromal cross-talk.
In conclusion, data presented in this study 
demonstrate that an HSV-1-based amplicon vector 
serves as a gene delivery system for U94. The ability 
of U94 to block cancer cell growth and metastasis by 
promoting a partial MET, together with its ability to 
impair vasculogenesis, highlights the complex antitumor 
activity of a virally-encoded protein, thus opening the way 
to a new promising field of research. Interestingly, U94 is 
homologous to Rep78, a non-structural protein from the 
human parvovirus adeno-associated virus type 2 [43] that 
displays antiproliferative effects on tumor cells [44]. This 
evidence indicates that U94 and Rep78 constitute a first 
group of viral proteins that have evolved mechanisms to 
control cell proliferation and could therefore be harnessed 
for cancer therapy. Overall, our findings open the way 
to study viruses that normally live in and among us for 
genetic blueprints that enable them to make molecules that 
act like drugs and might serve as the basis for new human 
anticancer therapeutics.
MATERIALS AND METHODS
Cell cultures
Human breast cancer cells (MDA-MB 231) and 
human cervical cancer cells (HeLa) were obtained 
from the American Type Culture Collection and grown 
as described. Human umbilical vein endothelial cells 
(HUVECs) and african green monkey kidney cells (Vero 
2-2) were cultured as previously described [6, 45].
Construction, production and titration of U94-
expressing herpes simplex type -1 (HSV-1) 
amplicon vectors
U94 (originated from HHV-6 type B) was amplified 
with the following primers: the forward primer, 5'-CTTT
GTCGACACCATGTTTTCCATAATAAATC-3'; and the 
reverse primer, 5'-CTTTGTCGACTTATAAAATTTTCG
GAACCGTG-3' using plasmid U94 pSR2PH vector as 
template (8). The PCR product was inserted into pHSVS, 
which contains an internal ribosomal entry site (IRES) of 
poliovirus [45] and supports the simultaneous expression 
of U94 and EGFP. Helper virus-free HSV-1 amplicon 
vector stocks were prepared as previously described [46]. 
The HSV-1 genome was provided in trans by a bacterial 
artificial chromosome (BAC) containing the HSV-1 
genome with deletions in the DNA cleavage/packaging 
signals and the essential ICP27 gene (fHSVΔpacΔICP27). 
Vero 2-2 cells were co-transfected with amplicon plasmid 
DNA, the fHSVΔpacΔICP27 BAC DNA, and plasmid 
pEBHICP27 (which provides the HSV-1 ICP27 gene in 
trans), using Lipofectamine LTX and Plus Reagent (Life 
Technologies). After 72 h, cells were lysed and debris were 
removed by centrifugation. Vero 2-2 cells were infected 
with the amplicon stocks and, after 24 h, green fluorescent 
cells were counted using an inverted fluorescence. The 
titers were determined as transducing units (TU)/ml and 
ranged between 2 x 106 and 8 x 106 TU/ml.
Cell infection
Infection of tumor cells was performed by 
incubating cells for 3 h in serum-free medium containing 
or not U94 and/or EGFP-expressing amplicons at different 
multiplicity of infection (MOI). Cells were then washed 
and incubated for 24 h in complete medium. Infection 
efficiency was assessed by flow cytometry.
Real-time and RT-PCR analysis
Total RNA was extracted from cells with RNeasy 
Plus Mini Kit (QIAGEN) and reverse transcribed. The 
following primers were used to perform PCR: U94:the 
forward primer, 5'-TCTCTAACGTGTCCGTGCC-3'; and 
the reverse primer, 5'- CATCGCATACGTCTCCCAG-3'; 
human β-actin: the forward primer, for 5'-GGCACC 
CAGCACAATGAAG-3', and the reverse primer 5'-GCT 
GATCCACATCTGCTGG-3'. Real-time PCR was 
performed using the following primers: human TWIST: the 
forward primer, 5'-CAGACGCAGCGGGTCATG-3'; and 
the reverse primer, 5'-AGGGCAGCGTGGGGATGA-3'; 
human SNAIL1: the forward primer, 5'-TGACCTGTC 
TGCAAATGCTC-3'; and the reverse primer, 5'-CAGA 
CCCTGGTTGCTTCAA-3'; human MMP2: the forward 
primer, 5'-GTATGGCTTCTGCCCTGAGA-3'; and the 
reverse primer, 5'-CACACCACATCTTTCCGTCA-3'; 
human N-cadherin: the forward primer, 5'-CAACTT 
GCCAGAAAACTCCAGG-3'; and the reverse primer, 
5'-ATGAAACCGGGCTATCTGCTC-3'; human GAPDH: 
the forward primer, 5'-GAAGGTCGGAGTCAAC 
GGATT-3'; and the reverse primer, 5'-TGACGG 
TGCCATGGAATTTG-3'.
Cell viability assay and flow cytometric assay of 
DNA content
Cell viability was evaluated with the Cell Titer–
Glo®Luminescent Cell Viability Assay (Promega). 
Twenty-four h p.i., EGFP+ and U94+ cells, as well as 
NT cells, were seeded in 96-well plates at a density of 
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5 x 103 cells/well. The CellTiter–Glo reagent was then 
added to each well at different time points and lysis 
reaction was carried out for 10 min on an orbital shaker. 
ATP luminescence intensity was measured using the 
GloMax® 20/20 Luminometer. Twenty-four h p.i., EGFP+, 
U94+ and NT cells were also seeded in 24-well plates at 
a density of 1 x 105 cells/well and passaged 1:2 when 
they were grown to approximately 80% confluence. At 
the indicated times, cells were trypsinized, inactivated 
with the addition of serum and counted using trypan blue 
exclusion. For performing flow cytometry, harvested cells 
were washed in PBS, resuspended in PBS containing 
0.5% EDTA (SigmaAldrich) and fixed in 99% ethanol for 
12 h at 4°C. Then cells were stained for 3 h at 4°C with 
PBS containing 2% FBS, 12.5 μg/ml DNase-free RNase 
A (SigmaAldrich) and 40 μg/ml of propidium iodide 
(SigmaAldrich). The percentage of G1, S, and G2/M phases 
of the cell cycle was measured using the MACSQuant® 
Analyzer (Miltenyi Biotec) and analysed using the FlowJo 
vX.07 software (Tree Star).
Wound healing assay
The wound healing assay was performed as 
previously described [47]. Briefly, cells were cultured 
into 24-well plates until confluence. Twenty-four h p.i., 
the monolayer was scratched using a 200 μl pipette tip 
and cultured in complete medium. In some experiments, 
confluent HUVEC monolayers were scratched and 
cultured in the presence of conditioned medium from 
infected or not infected tumor cells. Cell migration was 
evaluated at different time points.
Cell motility assay
Cell motility assay was performed as previously 
described [8]. Briefly, cells were seeded on the bottom of 
the flasks at a concentration of 105 cells/flask and allowed 
to adhere by overnight incubation at 37°C. Twenty-four 
h p.i., flasks were positioned at an ~ 20°C angle. At day 
8, migrated cells were stained with Diff-quick (Medion-
Diagnostics). Cell motility rates were analyzed by 
measuring the distance from the edge of the flask to the 
leading edge of the cells.
Invasion assay
Cell invasion assay was carried out by Matrigel-
coated transwell system. Polycarbonate transwell filters 
(8 μm pore size, Corning) were coated with 50 μg of 
basement membrane extract (BME; 10 mg/ml; Cultrex) 
diluted in a total volume of 150 μl of serum-free 
medium. Then the transwells were placed in a 24 well/
plate. Twenty-four h p.i., EGFP+ and U94+ cells, as well 
as not treated (NT) cells were serum starved for 24 h, 
trypsinized, resuspended in 150 μl of serum-free medium 
and seeded into the coated filter at a concentration of 
104 cells/well. Six hundred μl of complete medium were 
added into the lower chamber to take advantage of FBS as 
chemoattractant factor. The plate was incubated at 37°C 
and allowed to migrate through the matrigel-coated filter. 
After 48 h of incubation, cells that had crossed the filter 
were fixed, stained with Diff-Quick and counted.
Soft agar anchorage-independent growth assay
Soft agar assay was performed as previously 
described [48]. Twenty-four h p.i., EGFP+ and U94+ cells, 
as well as not treated (NT) cells (500/well) were plated 
in 2 ml of 0.5% agarose, 5% charcoal-stripped FBS in 
DMEM, with a 0.7% agarose base in six-well plates. 
One day after plating, complete medium was added to 
the top of the layer and replaced every four days. After 
10 days, 200 μl of 3-[4, 5-Dimethylthiazol-2-y1]-2, 
5-diphenyltetrazolium bromide (MTT, Sigma) were added 
to each well and allowed to incubate for 4 h at 37ºC. 
Colonies >50 mm diameter were counted.
Western blot analysis
Cells (2×106) were infected or not with different 
amplicons, cultured for 24 h and then processed as 
previously described [49]. The blots were incubated 
overnight at 4°C with mAbs to Src pTyr418 and Src 
(Invitrogen), β-catenin pTyr654 and β-catenin (Abcam), 
FAK pTyr397 and FAK (Invitrogen), STAT3 pTyr705 and 
STAT3 (Cell Signaling), Cortactin pTyr421 and Cortactin 
(Cell Signaling), ARP3 and GAPDH (Cell Signaling), Akt 
pSer473 and Akt (Cell Signaling), or ERK pThr202 and 
ERK (Santa Cruz Biotechnology). The antigen–antibody 
complex was detected using peroxidase-conjugated goat 
anti-mouse or anti-rabbit IgG (Thermo Scientific) and 
revealed using the enhanced chemiluminescence (ECL) 
system (Santa Cruz Biotechnology).
3D cell culture
Twenty-four h p.i., EGFP+ and U94+ cells, as well as 
not treated (NT) cells, were trypsinized and seeded at the 
density 1x106 cells/ml in the culture chamber of the Rotary 
Cell Culture System (RCCSTM) allowing the culture in 
3D dynamic microenvironment. Three D cultures were 
performed for 48 h in the RCCS bioreactor.
In vivo studies
Animal experiments were approved by our local 
animal ethics committee and were executed in accordance 
with national and international laws and policies (EEC 
Council Directive 86/609, OJ L 358, 12 December 1987). 
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Twenty-four h p.i., EGFP+ and U94+, as well as not treated 
(NT), MDA-MB 231 (5x106) or HeLa (3x106) cells 
were injected into the dorsolateral flank of 7 week-old 
NOD/SCID female mice. Tumors were measured in two 
dimensions and tumor volume was calculated according to 
the formula V=(D x d2)/2, where D and d are the major and 
minor perpendicular tumor diameters, respectively. At the 
end of the experimental procedure tumors were harvested, 
weighted, photographed and paraffin-embedded for IHC.
For experimental metastases, NT, EGFP+ or U94+ 
cells (1x106) were suspended in 100 μl of PBS and injected 
into the tail vein of 7 week-old NOD/SCID female mice. 
After 5 weeks lungs were harvested, formalin-fixed and 
the number of metastases were counted under a dissecting 
microscope.
IHC
After 3D culture and tumor growth in mice, cells 
and biopsies were harvested and processed as previously 
described [11]. Cell pellets and biopsies were fixed in 
10% buffered formalin and embedded in paraffin. Five μm 
thick sections were prepared and stained with H&E for 
morphological analysis. Sections for IHC were transferred 
to glass slides coated with poly-lisine, deparaffinized in 
100% xylene, and rehydrated in graded ethanol. After 
heat-induced antigen retrieval, endogenous peroxidase 
activity was inhibited with 3% hydrogen peroxide for 15 
s at room temperature, while aspecific epitope binding 
was blocked by incubation for 20 min with 20% human 
serum. Each section was then incubated for 30 min with 
monoclonal antibody to β-catenin (diluition: 1:120; Cell 
Marque), vimentin (diluition 1:150; Leica Biosystems), 
E-cadherin (diluition 1:50; Invitrogen) or with rabbit 
polyclonal antibody to mouse CD31 (dilution 1:50; 
Abcam). A biotin free polymeric-horseradish peroxidase-
linker antibody conjugate system (Bond Polymer Define 
Detection; Leica Biosystems) was used on the Bond Max 
automated immunostainer (Leica). 3-3' Diaminobenzidine 
Tetrahydrocloride (DAB) was used as substrate chromogen 
and Haematoxylin for nuclear counterstaining. Appropriate 
negative and positive control slides were run in parallel.
Cell co-cultivation and in vitro tube formation 
assay
Co-culture between MDA-MB 231 and HUVEC 
cells was performed in absence of direct cell contact by 
using transwell inserts (polycarbonate filters, coated with 
collagene, 0.4 μm pore size, Corning). Briefly, 24 h p.i., 
EGFP+ and U94+ as well as not treated (NT) MDA-MB 
231 cells were seeded directly in the transwell bottom 
well and HUVECs on the collagen-coated insert. After 
24 h, cells in the upper well were trypsinized and used to 
perform the tube formation assay [50].
Statistical analysis
Data obtained from multiple independent 
experiments are expressed as the mean ± SD. Data were 
analyzed for statistical significance using the 1-way 
ANOVA, and Bonferroni post-test was used to compare 
data. Student’s t test for unpaired data (2-tailed) was 
used to test the probability of significant differences 
between two groups of samples. Tumor volume data were 
statistically analyzed with a 2-way analysis of variance, 
and individual group comparisons were evaluated by 
the Bonferroni correction. Differences were considered 
significant when P < 0.05. Statistical tests were performed 
using GraphPad Prism 5 software.
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